SCHEMBL2716441

SCHEMBL2716441

O=C(Nc1ccc(OC(F)(F)F)cc1)NC1CCN(C(=O)c2ccncc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 20/20 1.00
EPHX1 P07099 3/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3216677 0.89 EPHX2 (1.00) EPHX2EPHX1
SCHEMBL28877776 0.88 EPHX2 (0.78) EPHX2EPHX1
SCHEMBL4305371 0.86 EPHX2 (0.78) EPHX2EPHX1
SCHEMBL4303092 0.86 EPHX2 (0.78) EPHX2EPHX1
SCHEMBL14997555 0.86 EPHX2 (0.75) EPHX2EPHX1
SCHEMBL17130358 0.85 EPHX2 (1.00) EPHX2EPHX1
SCHEMBL2719864 0.85 EPHX2 (1.00) EPHX2EPHX1
SCHEMBL4304785 0.85 EPHX2 (0.74) EPHX2EPHX1
SCHEMBL4304174 0.85 EPHX2 (0.81) EPHX2EPHX1
SCHEMBL4015938 0.85 EPHX2 (0.74) EPHX2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528604-B1 ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE UNIV CALIFORNIA (US) 2017-11-22 EP disclosed
EP-2528604-B1 ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE UNIV CALIFORNIA (US) 2017-11-22 EP disclosed
US-20160200683-A1 ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE UNIV CALIFORNIA (US) 2016-07-14 US disclosed
US-20160200683-A1 ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE UNIV CALIFORNIA (US) 2016-07-14 US disclosed
US-9296693-B2 Acyl piperidine inhibitors of soluble epoxide hydrolase THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-03-29 US disclosed
US-9296693-B2 Acyl piperidine inhibitors of soluble epoxide hydrolase THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-03-29 US disclosed
US-20130143925-A1 ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-06-06 US disclosed
US-20130143925-A1 ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-06-06 US disclosed
EP-2528604-A2 ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE The Regents of The University of California (US) 2012-12-05 EP disclosed
WO-2012054093-A2 ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-04-26 WO disclosed
US-20090270382-A1 Soluble epoxide hydrolase inhibitors ARETE THERAPEUTICS, INC. 2009-10-29 US disclosed
US-20090270382-A1 Soluble epoxide hydrolase inhibitors ARETE THERAPEUTICS, INC. 2009-10-29 US disclosed
US-20090270382-A1 Soluble epoxide hydrolase inhibitors ARETE THERAPEUTICS, INC. 2009-10-29 US disclosed
WO-2009129508-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270382-A1 Soluble epoxide hydrolase inhibitors EPHX1, EPHX2, LTA4H EPHX2 2/4885EPHX1 1/4885
US-20130143925-A1 ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE EPHX1, FAAH, FAAH2 EPHX2 4/4885EPHX1 1/4885
US-20160200683-A1 ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE EPHX1, FAAH, FAAH2 EPHX2 4/4885EPHX1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.